Xeris Biopharma Holdings, Inc. 4

Insider Kevin McCulloch had 21,918 Xeris Biopharma common shares withheld for tax purposes upon RSU vesting and now directly owns 1,654,208 shares, with 25,000 more held by his spouse.

On August 1, 2026, Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., had 21,918 shares of common stock withheld by the issuer at an implied price of $8.08 per share (approximately $177,080 in value) to satisfy income tax and withholding obligations arising from the net settlement of vested restricted stock units, a non-open-market, tax-related transaction. Following this withholding, he reported direct beneficial ownership of 1,654,208 shares of common stock, while an additional 25,000 shares are held indirectly by his spouse, for which he disclaims beneficial ownership beyond his pecuniary interest.

Filing Facts

CIK

1867096

Ticker

XERS

Form

4

Source Type

fda

Accession

0001867096-26-000069

Alert Tier

5